Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15527206 | 0.98 | KMT2A (0.39) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| Benzoic Acid SCHEMBL8013438 | 0.92 | TSHR (0.45) | KMT2AMEN1ATML3MBTL1POLB | |
| SCHEMBL4373512 | 0.82 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| SCHEMBL4210973 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| SCHEMBL27920579 | 0.80 | PRSS1 (0.58) | ALDH1A1KMT2AMEN1POLBLMNA | |
| Hydrochloric Acid SCHEMBL8764185 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| SCHEMBL8628714 | 0.79 | CA2 (0.41) | ALDH1A1KMT2AMEN1POLBCASP6 | |
| SCHEMBL175271 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| SCHEMBL28950933 | 0.78 | NPSR1 (0.48) | ALDH1A1KMT2AMEN1ATMTLR9 | |
| SCHEMBL11880568 | 0.77 | MEN1 (0.38) | ALDH1A1KMT2AMEN1ATMTLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | SALTER RHYS (CH) | 2012-12-13 | — | — | US | disclosed |
| CN-101198601-B | Methods and intermediates for the preparation of optionally radio-labeled imatinib | NOVARTIS AG | 2011-09-07 | — | — | CN | disclosed |
| US-20090299064-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | SALTER RHYS | 2009-12-03 | — | — | US | disclosed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| CN-101198601-A | Methods and intermediates for the preparation of optionally radio-labeled imatinib | NOVARTIS AG (CH) | 2008-06-11 | — | — | CN | disclosed |
| EP-1896447-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006133904-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-5175365-A | Preemergence herbicide 1- alpha-ethylbenzyl!-3-nitroguanidine | AMERICAN CYANAMID COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| US-4944788-A | Substituted nitro and cyanoguanidines and their use for increasing crop yields | AMERICAN CYANAMID COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| US-4804780-A | PLANT GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0113070-B1 | THE USE OF SUBSTITUTED NITRO AND CYANOGUANIDINES FOR INCREASING CROP YIELD | AMERICAN CYANAMID COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| EP-0210446-A2 | Nitro- and cyanoguanidines as selective preemergence herbicides and plant defoliants | AMERICAN CYANAMID COMPANY (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4639268-A | Nitro- and cyanoguanidines as selective preemergence herbicides and plant defoliants | AMERICAN CYANAMID COMPANY (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0189579-A1 | Substituted nitro and cyanoguanidines and their use for increasing crop yield | AMERICAN CYANAMID COMPANY (US) | 1986-08-06 | — | — | EP | disclosed |
| US-4594092-A | Cytokinin-like response | AMERICAN CYANAMID COMPANY (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0113070-A1 | The use of substituted nitro and cyanoguanidines for increasing crop yield | AMERICAN CYANAMID COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ALDH1A1 376/4885KMT2A 3738/4885MEN1 3644/4885 |
| US-20090299064-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | ABL1, PDGFRB, PDGFRA | ALDH1A1 155/4885KMT2A 545/4885MEN1 1336/4885 |
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | ABL1, PDGFRB, PDGFRA | ALDH1A1 151/4885KMT2A 567/4885MEN1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.